Abstract
Nociceptin (known also as orphanin FQ) is the most recently discovered member of the endogenous opioid peptide family, albeit nearly 15 years ago. Nociceptin renders or influences many behavioral, psychological and neurobiological processes, including memory, anxiety, stress and reward. Since its discovery, results of a steady stream of studies have suggested that endogenous nociceptin might be involved in responses to addictive drugs, and that targeting the nociceptin system may be beneficial in treating addictions. The current review summarizes and critically appraises those studies, particularly those that point to an application in treating alcoholism. Overall, most studies suggest that the endogenous nociceptin system has a physiological role in mediating or regulating behavioral responses to alcohol, and that activating nociceptin receptors suppresses ongoing alcohol consumption or reinstatement of responding for alcohol. These findings encourage the development of therapies targeted at the nociceptin system for the treatment of alcoholism in humans, though a minor number of studies showing continuous activation of the nociceptin receptor can produce increased, rather than reduced, alcohol consumption emphasize the necessity of further investigation.
Keywords: Nociceptin, orphanin FQ, opioids, alcohol, addiction, alcoholism
CNS & Neurological Disorders - Drug Targets
Title: The Nociceptin/Orphanin FQ System as a Target for Treating Alcoholism
Volume: 9 Issue: 1
Author(s): Niall P. Murphy
Affiliation:
Keywords: Nociceptin, orphanin FQ, opioids, alcohol, addiction, alcoholism
Abstract: Nociceptin (known also as orphanin FQ) is the most recently discovered member of the endogenous opioid peptide family, albeit nearly 15 years ago. Nociceptin renders or influences many behavioral, psychological and neurobiological processes, including memory, anxiety, stress and reward. Since its discovery, results of a steady stream of studies have suggested that endogenous nociceptin might be involved in responses to addictive drugs, and that targeting the nociceptin system may be beneficial in treating addictions. The current review summarizes and critically appraises those studies, particularly those that point to an application in treating alcoholism. Overall, most studies suggest that the endogenous nociceptin system has a physiological role in mediating or regulating behavioral responses to alcohol, and that activating nociceptin receptors suppresses ongoing alcohol consumption or reinstatement of responding for alcohol. These findings encourage the development of therapies targeted at the nociceptin system for the treatment of alcoholism in humans, though a minor number of studies showing continuous activation of the nociceptin receptor can produce increased, rather than reduced, alcohol consumption emphasize the necessity of further investigation.
Export Options
About this article
Cite this article as:
Murphy P. Niall, The Nociceptin/Orphanin FQ System as a Target for Treating Alcoholism, CNS & Neurological Disorders - Drug Targets 2010; 9 (1) . https://dx.doi.org/10.2174/187152710790966713
DOI https://dx.doi.org/10.2174/187152710790966713 |
Print ISSN 1871-5273 |
Publisher Name Bentham Science Publisher |
Online ISSN 1996-3181 |
Call for Papers in Thematic Issues
Diagnosis and treatment of central nervous system infectious diseases
Infectious diseases of the central nervous system (CNS) can be divided into bacterial, tuberculous, viral, fungal, parasitic infections, etc. Early etiological treatment is often the most crucial means to reduce the mortality rate of patients with central nervous system infections, reduce complications and sequelae, and improve prognosis. The initial clinical ...read more
Trends and perspectives in the rational management of CNS disorders
Central nervous system (CNS) diseases enforce a significant global health burden, driving ongoing efforts to improve our understanding and effectiveness of therapy. This issue investigates current advances in the discipline, focusing on the understanding as well as therapeutic handling of various CNS diseases. The issue covers a variety of diseases, ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Severe Acute Respiratory Syndrome Coronavirus 2 is Penetrating to Dementia Research
Current Neurovascular Research Role of Flavonoids in Neurodegenerative Diseases: Limitations and Future Perspectives
Current Topics in Medicinal Chemistry Morphologic Characterization of PhoenixBio® (uPA+/+/SCID) Humanized Liver Chimeric Mouse Model
Drug Metabolism Letters Polymorphisms at the LDLR Locus may be Associated with Ischemic Cerebrovascular Disease Independent of Lipid Profile
Current Neurovascular Research Madecassic Acid Reduces Fast Transient Potassium Channels and Promotes Neurite Elongation in Hippocampal CA1 Neurons
CNS & Neurological Disorders - Drug Targets Synthesis of LDH Nanosheets and their Layer-by-Layer Assembly
Recent Patents on Nanotechnology Autoantibody-Induced Formation of Immune Complexes in Normal Human Serum
Current Pharmaceutical Design The Role of αA-Crystallin in Experimental Autoimmune Uveitis
Current Molecular Medicine Essential Structural Features of Novel Antischizophrenic Drugs: A Review
Medicinal Chemistry Novel and Emerging Targeted Therapies of Colorectal Cancer
Current Clinical Pharmacology Tumour Necrosis Factor α Gene Promoter and its Role in Rheumatoid Arthritis Outcome and Pharmacogenetics
Current Pharmacogenomics Calcium Channel Blockers in the Management of Hypertension in the Elderly
Cardiovascular & Hematological Agents in Medicinal Chemistry Pharmacological Inhibition of the Bcl-2 Family of Apoptosis Regulators as Cancer Therapy
Current Molecular Pharmacology Small Molecular Inhibitors of p-STAT3: Novel Agents for Treatment of Primary and Metastatic CNS Cancers
Recent Patents on CNS Drug Discovery (Discontinued) Nanomaterial Based Approaches for the Diagnosis and Therapy of Cardiovascular Diseases
Current Pharmaceutical Design Sulfation in Dog
Current Drug Metabolism TLR3 and TLR4 But not TLR2 are Involved in Vogt-Koyanagi- Harada Disease by Triggering Proinflammatory Cytokines Production Through Promoting the Production of Mitochondrial Reactive Oxygen Species
Current Molecular Medicine PET Tracers for Serotonin Receptors and Their Applications
Central Nervous System Agents in Medicinal Chemistry Blood-Brain Barrier Transport of Drugs for the Treatment of Brain Diseases
CNS & Neurological Disorders - Drug Targets Non-Monoaminergic Targets for the Development of Antidepressants: Focus on Neuropeptides
Mini-Reviews in Medicinal Chemistry